Zaprinast

• CAT Number: R000561
• CAS Number: 37762-06-4
• Molecular Formula: C13H13N5O2
• Molecular Weight: 271.28
• Purity: ≥95%
• Synonyms: 3,6-dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidin-7-one; 1,4-Dihydro-5-[2-propoxyphenyl]-7H-1,2,3-triazolo[4,5-d]pyrimidine-7-one; 8-Aza-2-(2-propoxyphenyl)-6-purinone; M&B 22,948
• Target: GPCR/G Protein
• Solubility: Soluble in DMSO > 10 mM
• Storage: Store at RT
• IUPAC Name: 5-(2-propoxyphenyl)-2,3-dihydrotriazolo[4,5-d]pyrimidin-7-one
• InChI: InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)
• InChIKey: REZGGXNDEMKIQB-UHFFFAOYSA-N
• SMILES: CCCOC1=CC=CC=C1C2=NC(=O)C3=NNNC3=N2

Zaprinast is a phosphodiesterase (PDE) inhibitor, primarily targeting PDE5 and PDE6 enzymes. It was initially developed as a potential treatment for cardiovascular diseases due to its ability to increase cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation and improved blood flow. While zaprinast was not widely adopted clinically, it paved the way for the development of more effective PDE5 inhibitors like sildenafil (Viagra). Zaprinast is still used in research to study cyclic nucleotide signaling pathways and has shown potential in areas such as pulmonary hypertension and erectile dysfunction research. It also has applications in studying smooth muscle relaxation and related pharmacological effects.